Promising new approach to treating some of the worst types of leukaemia

December 11, 2019

New therapy shows 'dramatic' effect against worst leukaemias

A collaborative research effort by Australian and US scientists has led to the discovery of a promising new approach to treating some of the worst types of leukaemia, including an aggressive leukaemia that mostly affects babies.

MLL-rearranged leukaemia (MLL-r leukaemias) is a subtype of leukaemia that has a particular genetic structure known as MLL rearrangement. This occurs in about 80% of acute leukemia cases in infants (children under one year of age) and up to 10% of all leukemia cases, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Often resistant to chemotherapy and extremely difficult to treat, MLL-r leukaemia claims the lives of many of those affected, while those who survive are often left with serious long-term effects due to the highly intensive treatment they are given.

The new research, to be published this month in the international journal Cancer Cell, describes a new therapy developed for MLL-r leukaemia as having 'outstanding pharmaceutical properties.' When used to treat specially-bred mice that were growing MLL-r leukaemia derived from human patients, the therapy produced a 'dramatic response', curing many of the mice. The researchers are hopeful that the new therapy will prove successful against MLL-r leukaemia in humans, and anticipate the rapid translation of their research into clinical trials.

'New therapeutic approaches are desperately needed for MLL-r leukaemia,' said Professor Richard Lock, Head of the Blood Cancers Theme at Children's Cancer Institute, Australia. 'The combination of drugs currently used for treatment is often not effective and causes significant side effects. This is undesirable in anyone, but is particularly a problem in children, whose growing bodies are very susceptible to the damaging effects of toxic drugs.'

The newly developed agent, a small molecule inhibitor called VTP50469, is one of a new breed of targeted therapies, named for the fact that they are designed to specifically target molecules that are critical for the survival and growth of cancer cells. Such therapies offer significant advantages over conventional drug treatments, since as well as being more effective, they cause far fewer side effects. In the case of MLL-r leukaemia, the molecules being targeted are Menin and MLL fusion proteins, which interact in leukaemia cells to drive the growth of the cells.

'What is particularly exciting about this new agent is that it shows remarkable anti-leukaemia activity when used on its own,' said Professor Lock. 'It is highly unusual to see a single agent cause such a dramatic response, so we are extremely optimistic that it will prove effective in humans.'
-end-
Media Contact

Children's Cancer Institute:
Ashleigh Addison
Director, Uptown Communications
(02) 8502 2272 | 0418 274 428

About Children's Cancer Institute

Originally founded by two fathers of children with cancer in 1976, Children's Cancer Institute is the only independent medical research institute in Australia wholly dedicated to research into the causes, prevention and cure of childhood cancer. Forty years on, our vision remains unchanged - to save the lives of all children with cancer and to eliminate their suffering. The Institute has grown to now employ nearly 300 researchers, operational staff and students, and has established a national and international reputation for scientific excellence. Our focus is on translational research, and we have an integrated team of laboratory researchers and clinician scientists who work together in partnership to discover new treatments which can be progressed from the lab bench to the beds of children on wards in our hospitals as quickly as possible. These new treatments are specifically targeting childhood cancers, so we can develop safer and more effective drugs and drug combinations that will minimize side-effects and ultimately give children with cancer the best chance of a cure with the highest possible quality of life. More at http://www.ccia.org.au

Children's Cancer Institute Australia

Related Leukaemia Articles from Brightsurf:

An area of the brain where tumor cells shelter from chemotherapy in childhood leukaemia
Sometimes, the central nervous system harbours tumour cells that elude treatment and thus become one of the main sources of relapse.

Feline leukaemia virus infection: A clinical and epidemiological enigma
Feline leukaemia virus (FeLV) is a gammaretrovirus that occurs worldwide in domestic cats, as well as small wild cats.

Decades old mystery in leukaemia treatment solved
A research team led by the University of Kent and Goethe-University Frankfurt am Main, has solved an almost 40-year old mystery in leukaemia therapy and the drug nelarabine, thanks to studying levels of enzyme SAMHD1.

Treating leukaemia more effectively
Acute lymphoblastic leukaemia (ALL) is the most common kind of cancer in children.

Targeting stem cells: The path to curing poor-prognosis leukaemia
Researchers have been investigating what they believe to be the root cause of treatment resistance, leukaemia stem cells, and have now hit upon a new therapeutic approach that works by targeting these cells.

Promising new approach to treating some of the worst types of leukaemia
'New therapeutic approaches are desperately needed for MLL-r leukaemia,' said Professor Richard Lock, Head of the Blood Cancers Theme at Children's Cancer Institute, Australia.

Leukaemia cells can transform into non-cancerous cells through epigenetic changes
Researchers of the Josep Carreras Leukaemia Research Institute discover that a leukaemic cell is capable of transforming into a non-cancerous cell through epigenetic changes.

Published a clinical guide for the genomic diagnosis of Myelodysplastic Syndromes and Chronic Myelomonocytic leukaemia
A collective work between researchers from 8 research centres and hospitals in Spain, coordinated by Francesc Solé of the Josep Carreras Leukaemia Research Institute (IJC), and Esperanza Such, of the University and Polytechnic Hospital de la Fe describes the recommendations of use of the Next Generation genome Sequencing (NGS) in the diagnosis of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Old cells, new tricks -- important clue to AML diagnosis and cure discovered
Around 22,000 people will be diagnosed this year in the US with acute myeloid leukemia (AML), the second most common type of leukemia diagnosed in adults and children.

New drug providing hope for babies with aggressive Acute Lymphoblastic Leukaemia
A breakthrough new drug is providing hope to tiny babies at risk of dying from an aggressive form of Acute Lymphoblastic Leukaemia and could help all cancer patients.

Read More: Leukaemia News and Leukaemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.